Literature DB >> 20609615

Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks.

James T Metz1, Philip J Hajduk.   

Abstract

Many successful drugs bind to and modulate multiple targets in vivo. Successfully navigating protein-ligand polypharmacology will be a crucial and increasingly utilized component of pharmaceutical research. As publicly available databases of ligand activity values continue to grow in size and quality, infrastructure is needed to enable scientists to create and interact with these networks to fuel hypothesis-driven science. While most of the individual tools for creating this infrastructure exist, effectively connecting the data to the network to the scientist is very much a work in progress. Standards for publishing network data are also important to facilitate the analysis and comparison of networks from different research groups using different methods. 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20609615     DOI: 10.1016/j.cbpa.2010.06.166

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  20 in total

Review 1.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Navigating the kinome.

Authors:  James T Metz; Eric F Johnson; Niru B Soni; Philip J Merta; Lemma Kifle; Philip J Hajduk
Journal:  Nat Chem Biol       Date:  2011-02-20       Impact factor: 15.040

3.  Getting pharmaceutical R&D back on target.

Authors:  Mark E Bunnage
Journal:  Nat Chem Biol       Date:  2011-06       Impact factor: 15.040

4.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

5.  Proteochemometric model for predicting the inhibition of penicillin-binding proteins.

Authors:  Sunanta Nabu; Chanin Nantasenamat; Wiwat Owasirikul; Ratana Lawung; Chartchalerm Isarankura-Na-Ayudhya; Maris Lapins; Jarl E S Wikberg; Virapong Prachayasittikul
Journal:  J Comput Aided Mol Des       Date:  2014-10-26       Impact factor: 3.686

6.  The multi-target effects of CNI-1493: convergence of anti-amylodogenic and anti-inflammatory properties in animal models of Alzheimer's disease.

Authors:  Roman Sankowski; Arne Herring; Kathy Keyvani; Kathrin Frenzel; Jinyu Wu; Stephan Röskam; Carmen Noelker; Michael Bacher; Yousef Al-Abed
Journal:  Mol Med       Date:  2016-11-15       Impact factor: 6.354

7.  Characterizing protein domain associations by Small-molecule ligand binding.

Authors:  Qingliang Li; Tiejun Cheng; Yanli Wang; Stephen H Bryant
Journal:  J Proteome Sci Comput Biol       Date:  2012-12-03

8.  Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.

Authors:  Benjamin W Jester; Alicia Gaj; Carolyn D Shomin; Kurt J Cox; Indraneel Ghosh
Journal:  J Med Chem       Date:  2012-02-10       Impact factor: 7.446

9.  Dealing with the Data Deluge: Handling the Multitude Of Chemical Biology Data Sources.

Authors:  Rajarshi Guha; Dac-Trung Nguyen; Noel Southall; Ajit Jadhav
Journal:  Curr Protoc Chem Biol       Date:  2012-09-01

Review 10.  A generalizable pre-clinical research approach for orphan disease therapy.

Authors:  Chandree L Beaulieu; Mark E Samuels; Sean Ekins; Christopher R McMaster; Aled M Edwards; Adrian R Krainer; Geoffrey G Hicks; Brendan J Frey; Kym M Boycott; Alex E Mackenzie
Journal:  Orphanet J Rare Dis       Date:  2012-06-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.